CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia

Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04157569

Enrollment

200

Registered

2019-11-08

Start date

2019-11-05

Completion date

2029-12-31

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia

Brief summary

This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL

Detailed description

This study will use droplet digital PCR (ddPCR) method to quantify peripheral blood plasma mutant allele frequency (MAF) in elderly acute leukemia patients after chemotherapy to evaluate the clinical value of CtDNA .

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * Male * not pregnant female * patients \>=60 years old * Diagnosis of acute leukemia

Exclusion criteria

* Pregnancy * HIV positive * patients \>=100 years old

Design outcomes

Primary

Measure	Time frame	Description
cumulative incidence of relapse(CIR)	through study completion, an average of 1 year	cumulative incidence of relapse

Secondary

Measure	Time frame	Description
overall survival (OS)	through study completion, an average of 2 years	overall survival

Countries

China

Contacts

Primary ContactLiren Qian, MD

qlr2007@126.com+861066957676

Outcome results